A world free of malaria?

Merck Collaborates to Research Potential Malaria Vaccine

Merck's recently announced partnership with New York University Langone Medical Center and the PATH Malaria Vaccine Initiative (MVI) is focused on creating a vaccine that prevents an essential early stage of malaria infection: the invasion of the malaria parasite into the human liver.

The partnership leverages Merck's own expertise and scientific know-how along with The New York University Langone Medical Center's extensive research in the field and MVI's critical funding capabilities.

Merck Donates Antimalarial Candidate to Medicines for Malaria Venture

In 2009, Merck announced a licensing agreement with Medicines for Malaria Venture (MMV), a
not-for-profit virtual research and development organization dedicated to reducing the burden of malaria, for an investigational drug candidate for the treatment of malaria in the developing world.

Merck's Mectizan Donation Program Partner Distributes Bed Nets

A key partner in the Mectizan Donation Program is The Carter Center, which has integrated malaria and lymphatic filariasis activities. Since the same mosquito transmits both malaria and lymphatic filariasis, the distribution of bed nets can be used to prevent both diseases at once. In Nigeria more than 4 million bed nets have been distributed through programs assisted by The Carter Center.

MSD in Spain Enters R&D Partnership

Created in 2008, Fundación Medina is a non-profit public-private partnership between MSD in Spain, the Junta de Andalucia and the University of Granada, Spain. Medina focuses on the discovery of new compounds and innovative therapies for infectious diseases, including malaria.